

## Curriculum Vitae

**Martin W. McIntosh**

### *Education:*

1986: Michigan State University, East Lansing, Michigan, B.Sc., Computer Science  
1992: Harvard University, Cambridge, Massachusetts, A.M., Statistics  
1996: Harvard University, Cambridge, Massachusetts, Ph.D., Statistics

### *Positions:*

2000-present Assistant Member (Primary), Cancer Prevention Research Program, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington  
1999-present Faculty Member, Center for Statistics and Social Sciences (CSSS), University of Washington,  
1998-1999 Assistant Member (Joint), Cancer Prevention Research Program, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington  
1996-present Assistant Professor, Department of Biostatistics, University of Washington, Seattle, Washington

Research Scientist II, Bolt, Beranek and Newman (BBN), Cambridge, Massachusetts  
Computer Engineer, Wang Laboratories, Boston, Massachusetts

### *Additional Professional Training and Conferences:*

Cellular and Molecular Biology Training grant, Ovarian SPORE, October 2001 through October 2002.  
Annual NCI Special Programs in Research Excellence, Washington D.C., July 2001.  
Investigating heterogeneity in Meta-analyses, RAND Corp., Santa Monica, California, November 2000.  
Annual NCI Special Programs in Research Excellence, Chantilly, Virginia, July 2000.  
International Conference on Health Policy Research, Santa Monica, California, December 1999  
International Ovarian Cancer Screening Workshop, Dubrovnik, Croatia, September 1999  
International Breast Cancer Screening Network, Florence, Italy, August 1999  
Santa Fe Institute Interface of Experimental and Computational Biology, Seattle, Washington, April 1999  
Joint Statistical Meetings, Dallas, Texas, August 1998  
Understanding the Genome: Technological and Mathematical Challenges, Berkley, California, May 1998  
Breast Cancer Research Consortium, April 1999 and April 1998

### *Affiliations and Professional Activities*

Molecular markers special topic co-chair, NCI Spore Program, July 2002.  
Co-Principle investigator, Ovarian SPORE Informatics CORE – September 2001 -- present  
Institutional Review Board, CRAB, August 2000 -- present  
Department of Defense Program in Breast Cancer Research, grant review panel, September 2001.  
Agency for Health Care Policy and Research ad-hoc grant review committee, July 1999.  
Member Core Faculty, Clinical Scholars Program, University of Washington, 1998-1999.

**April 2002**

Faculty member, Center for Statistics and the Social Sciences (CSSS), University of Washington, 1998-present.

Grant Review Committee, Veterans Health Administration, Health Services Research and Admissions Committee, University of Washington, 1997-1998.

Second year theory exam committee, University of Washington, Spring/Summer 1997.

Admissions Committee, University of Washington, Spring/Summer 1997, 1998, 1999;2000,2001.

**Articles in Refereed Journals**

1. **McIntosh, MW**, Urban, N, Karlan, B., Screening algorithms for novel tumor biomarkers markers, *Cancer Epidemiology, Biomarkers and Prevention*, 2002 11: 159-166.
2. Kneipp, S, **McIntosh, M.**, Handling Missing Data in Nursing Research with Multiple Imputations. *Nursing Research. Nurs Res.* 2001 Nov-Dec;50(6):384-9
3. Pauler, DK, Menor, U, **McIntosh, MW**, Symecko, HL, Skates, SJ, Jacobs, IJ, Factors influencing serum CA125II levels in healthy postmenopausal women, *Cancer Epidemiol Biomarkers Prev.* 2001 May;10(5):489-93.
4. **McIntosh, MW**, Ramsey S, Berry K, Urban N. Parameter Solicitation for Planning Cost Effectiveness Studies with Dichotomous Outcomes. *Health Economics.* 10(1), January 2001.
5. Ramsey, SD, **McIntosh, MW**, Sullivan, SD, Design Issues for Conducting Cost-Effectiveness Analyses Alongside Clinical Trials, *Annual Review of Public Health.* 22:129-41, January 2001.
6. Crump KC, **McIntosh, MW**, Urban N, Anderson G, Karlan B, Ovarian cancer tumor marker behavior in asymptomatic healthy women: Implications for screening. *Cancer-Epidemiology, Biomarkers, and Prevention*, 9(10): 1107-1111, October 2000.
7. **McIntosh, MW** and Rubin, DB, On estimating the causal effects of DNR orders (Review) *Med Care.* 37(8):722-6, August 1999.
8. **McIntosh, MW**, Instrumental variables for evaluating screening trials: estimating the benefit of detecting cancer by screening. *Stat Med.* 30;18(20):2775-94, October 1999.
9. Edlefsen KL, Mandelson MT, **McIntosh, MW**, Anderson MR, Wagner EH, Urban N, Prostate specific antigen for prostate cancer screening: Do physicians characteristics affect its use?, *American Journal of Preventive Medicine*, 17(1):87-90, 1999.
10. Ioannidis JP, Dixon DO, **McIntosh, MW**, Albert JM, Bozzette SA, Relationship between event rates and treatment effects in clinical site differences within multicenter trials: an example from primary *Pneumocystis carini* prophylaxis. *Controlled Clinical Trials.* 20(3):253-66, June 1999.
11. Schmid CH, Lau J, **McIntosh, MW**, Cappelleri JC, An empirical study of the effect of the control rate as a predictor of treatment efficacy in meta-analysis of clinical trials. *Statistics in Medicine.* 17(17):1923-42, Sept. 1998.
12. **McIntosh, MW**, The population risk as an explanatory variable in research synthesis of clinical trials. *Statistics in Medicine.* 15:1713-1728, 1997.
13. Zucker D, Schmid C, **McIntosh, MW**, Lau J, D'Augustino R, Combining single patient (N-of-1) trials to estimate population treatment effects and to evaluate individual patient response to treatment. *Journal of Clinical Epidemiology.* 50(4): 401-410, 1997.

**Accepted or in Press**

1. **McIntosh, MW**, Urban, N, A Parametric Empirical Bayes Method for Cancer Screening using Longitudinal Observations of a Biomarker, *Biostatistics.*
2. **McIntosh, MW**, Pepe, M, Combining several screening tests: the role of the Cancer Risk Score, *Biometrics.*

3. Lesley Tinker, Deborah Bowen, Martin McIntosh, Linda Miller Parker, Ruth Patterson, Michael Perri, Mary Ann Sevick, Lois Wodarski, Adherence factors in the WHI Dietary Modification Clinical Trial, *Behavioral Epidemiology*.
4. Andersen MR, Peacock S, Nelson J, Wilson S, **McIntosh M**, Urban N. Worry about ovarian cancer risk and use of ovarian cancer screening by women at risk for ovarian cancer, *Gynecologic Oncology*.
5. DuBois ML, Haimberger, ZW, **McIntosh, MW**, Gottschling, DE, Multiple telomeric components contribute to protective chromosomal caps in *S. cerevisiae*, *Genetics*.

#### Submitted to refereed journals

1. Schummer, M, Kiviat, N., Hood, L., Drescher, C., Pepe, M., Ben-Dor, A., **McIntosh, MW**, Siegel, A., Hellström, I., Hellström, K., Urban, N., Microarray-Based Gene Profiling Discovers Potential Ovarian Cancer Markers (*Nature/Genetics*).
2. **McIntosh, MW**, Drescher, C, Urban, N, Hellstrom, I, Hellstrom, K, “Mesothelion/MPF antigen(s) as a diagnostic and screening marker for ovarian carcinoma when used alone or combined with CA 125, *Cancer Epidemiology Biomarkers, and Prevention*.
3. Sow, PS, Diop, A, Diouf, MB, Hawes, SE, Critchlow, CW, **McIntosh, MW**, Starling, AK, Coll-Seck, AM, Kiviat, NB, Characteristics, signs and symptoms of persons presenting to an outpatient infectious disease clinic in Dakar, Senegal with previously undiagnosed HIV-1 or HIV-2 infection, *Aids*.

#### Other published scholarly manuscripts published or in-press.

1. **McIntosh, MW**. Book Review: Quantitative Methods for the Evaluation of Cancer Screening, *Statistics in Medicine*. Forthcoming (2002)
2. Urban N, **McIntosh, MW**, Clarke L, Jacobs I, Karlan B, Anderson G, Drescher C, Socioeconomics of Ovarian Cancer Screening, Book chapter in *Ovarian Cancer 6* , Oxford Press, February 2002
3. Ramsey SD, **McIntosh, MW**, Etzioni R, Urban N. Simulation Modeling of Outcomes and Cost-effectiveness. Book chapter in: *Hematology/Oncology Clinics of North America*. Allegra C and Kramer BS, editors, August 2000, 14(4), 925-38.
4. Antman, Elliott M, Seelig, Fleischmann M, Kirsten, Lau, Berkey C, **McIntosh, MW**, Magnesium in acute myocardial infarction: scientific, statistical and economic rationale for its use (invited editorial). *Cardiovascular Drugs and Therapy*. 10:297-301, 1996.

#### Selected Invited Talks

1. Improving diagnostic testing for ovarian cancer by combining tumor markers, 3rd Annual Ovarian Cancer Screening Workshop, Seattle WA, August 2001.
2. The complementarity of several ovarian cancer tumor markers for ovarian cancer screening, Spore Workshop, Washington D.C., July 2001.
3. Methods for combining tumor markers to improve diagnostic tests, SPORE Workshop, Washington D.C., July 2001.

4. Parametric Empirical Bayes Methods for Cancer Screening, FHRC Biostatistics, January 2001.
5. An insight on combining information from clinical studies, RAND Corporation, November 2000.
6. Selecting and Using Multiple Tumor Markers for Longitudinal Screening Algorithms, SPORE Workshop (Poster), Chantilly, Virginia, July 2000.
7. Model Based Methods for Screening with a Panel of Tumor Markers”, Diagnostic Methods Working Group (Margaret Pepe, Organizer), University of Washington Department of Biostatistics, April 2000.
8. Using Mixture Models for Selecting Markers for Cancer Screening, Model Based Clustering Working Group (Adrian Raftery, Organizer), University of Washington Department of Statistics, February 2000.
9. Perspectives on Micro-array analysis: Cancer screening and detection, with Garnet Anderson, University of Washington, January 2000.
10. Socioeconomics of Ovarian Cancer Screening, Presented at the International Conference on Health Policy Research, the RAND Corporation, Santa Monica, California, December 1999.
11. Formulating quality of life studies in the framework of missing data. Presented at the International Conference on Health Policy Research, the RAND Corporation, Santa Monica, California, December 1999.
12. The cost effectiveness of screening and the role of DCIS progression. Presented at the International Breast Screening Network conference, Florence, Italy, August 1999.
13. Statistical models for selecting and using cancer tumor markers for screening. Presented at the National Institute of Health, May 1999.
14. Characterizing the performance of tumor markers in longitudinal screening algorithms. Presented at Dartmouth University, New Hampshire, April 1999.
15. Semi-parametric methods for longitudinal screening for cancer using serum tumor markers. Presented at the University of California at San Francisco Medical School, San Francisco, California, October 1998.
16. Using multiple cancer markers in longitudinal screening for cancer. Presented at a workshop of the Marsha Rivkin Center for Ovarian Cancer Research Biennial Ovarian Cancer Research Symposium, Seattle, WA, September 1998.
17. Empirical Bayes method for sequential screening of cancer. Presented at Harvard University, Department of Statistics, Cambridge, MA, September 1998.
18. Using instrumental variables when evaluating cancer-screening trials: Estimating the benefit of detecting cancer by screening. Presented at the Statistical Joint Meetings, Dallas, Texas, August 1998.
19. Using instrumental variables when evaluating cancer screening trials: Estimating the benefit of detecting cancer by screening. Presented at Fred Hutchinson Cancer Research Center, Seattle, WA, February 1998.

20. Using instrumental variables when evaluating cancer screening trials: Estimating the benefit of detecting cancer by screening. Presented at the University of Michigan, Department of Statistics and Biostatistics, Ann Arbor, MI, January 1998.
21. Concepts and limitations of meta-analyses for clinical medicine. Presented to the University of Washington's Health Care Policy Department, November 1997.
22. Using compliance information when estimating causal effects on survival in randomized trials, Presented to the Biostatistics Department, University of Washington, November 1997.
23. Causal inference in experiments and observational studies. Presented to the Department of Psychology/Social Psychology, University of Washington, October 1997.
24. Hierarchical models to control for ecological parameters in meta-analyses of clinical trials. Presented at the University of Connecticut, Department of Statistics Colloquium, February 1996.